European countries with small populations can obtain low prices for drugs: Lithuania as a case history

References

• Barry M, Usher C, Tilson L. Public drug expenditure in the Republic of Ireland. Expert Rev. Pharmacoeconomics Outcomes Res.10, 239–245 (2010).
   PubMed Web of Science ®Google Scholar
• Coma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction. Expert Rev. Pharmacoeconomics Outcomes Res.9, 569–581 (2009).
   PubMedGoogle Scholar
• Godman B, Bucsics A, Burkhardt T et al. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoeconomics Outcomes Res.8, 357–371 (2008).
   PubMedGoogle Scholar
• Sermet C, Andrieu V, Godman B et al. Ongoing pharmaceutical reforms in France; considerations for other countries and implications for key stakeholder groups in France. Appl. Health Econ. Health Policy8, 7–24 (2010).
   PubMedGoogle Scholar
• Simoens S. Developing competitive and sustainable Polish generic medicines market. Croat. Med. J.50, 440–448 (2008).
   Web of Science ®Google Scholar
• Godman B, Shrank W, Wettermark B et al. Use of generics – a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals3, 2470–2494 (2010).
   Google Scholar
• Godman B, Shrank W, Andersen M et al. Comparing policies to enhance the utilisation generics across Europe: impact and global implications. Expert Rev. Pharmacoeconomics Outcomes Res.10, 707–722 (2010).
   PubMed Web of Science ®Google Scholar
• Garattini S, Bertele V, Godman B et al. Enhancing the rational use of new medicines across European healthcare systems – a position paper. Eur. J. Clin. Pharmacol.64, 1137–1138 (2008).
   PubMed Web of Science ®Google Scholar
• Gumbs P, Verschuren W, Souverein P et al. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. Br. J. Clin. Pharmacol.64, 680–685 (2007).
   PubMed Web of Science ®Google Scholar
• Lee T, Emanuel E. Tier 4 drugs and the fraying of the social compact. N. Engl. J. Med.359, 333–335 (2008).
   PubMed Web of Science ®Google Scholar
• Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front. Pharmacol.1, 1–16 (2011).
   Google Scholar
• Barrett A, Roques T, Small M, Smith R. How much will Herceptin really cost? BMJ33, 1118–1120 (2006).
   Google Scholar
• Traulsen J, Almarsdóttir A. The argument for pharmaceutical policy. Pharm. World Sci.27, 7–12 (2005).
   PubMedGoogle Scholar
• McKee M, Stuckler D, Martin-Moren J. Protecting health in hard times. BMJ341, 681–682 (2010).
   Google Scholar
• Wettermark B, Godman B, Eriksson C et al. [Introduction of new medicines into European healthcare systems]. GGW10(3), 24–34 (2010).
   Google Scholar
• Godman B, Haycox A, Schwabe U et al. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics26, 91–98 (2008).
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, Hoffman M et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev. Pharmacoeconomics Outcomes Res.9, 65–83 (2009).
   PubMedGoogle Scholar
• Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs. Pharmacoeconomics27, 1–4 (2009).
   PubMed Web of Science ®Google Scholar
• Godman B, Burkhardt T, Bucsics A et al. Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs; implications for the future. Expert Rev. Pharmacoeconomics Outcomes Res.9, 475–484 (2009).
   PubMedGoogle Scholar
• McGinn D, Godman B, Lonsdale J et al. Initiatives to enhance the efficiency of statin and proton pump inhibitor prescribing in the UK; impact and implications. Expert Rev. Pharmacoeconomics Outcomes Res.10, 73–85 (2010).
   PubMed Web of Science ®Google Scholar
• Simoens S. Generic medicine pricing in Europe: current issues and future perspective. J. Med. Economics11, 171–175 (2008).
   PubMedGoogle Scholar
• Wettermark B, Godman B, Andersson K et al. Recent national and regional drug reforms in Sweden – implications for pharmaceutical companies in Europe. Pharmacoeconomics26, 537–550 (2008).
   PubMed Web of Science ®Google Scholar
• Simoens S. International comparison of generic medicine prices. Curr. Med. Res. Opin.23, 2647–2265 (2007).
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B. Impact of reforms to enhance the quality and efficiency of statin prescribing across 20 European countries. Presented at: 9th Congress European Association for Clinical Pharmacology and Therapeutics. Edinburgh, Scotland, UK, 12–15 July 2009.
   Google Scholar
• Godman B, Wettermark B. Trends in consumption and expenditure of proton pump inhibitors (PPIs) in 20 European countries. Presented at: 9th Congress European Association for Clinical Pharmacology and Therapeutics. Edinburgh, Scotland, UK, 12–15 July 2009.
   Google Scholar
• Simoens S. Trends in generic prescribing and dispensing in Europe. Exp. Rev. Clin. Pharmacol.1, 497–503 (2008).
   PubMedGoogle Scholar
• Frank R. The ongoing regulation of generic drugs. N. Engl. J. Med.357, 1993–1996 (2007).
   PubMed Web of Science ®Google Scholar
• Jack A. Balancing big pharma’s books. Br. Med. J.336, 418–419 (2008).
   PubMed Web of Science ®Google Scholar
• Moon J, Flett A, Godman B et al. Getting better value from the NHS drug budget. Br. Med.341, c6449 (2010).
   PubMed Web of Science ®Google Scholar
• Kaduševičius E, Mikučionytė L, Mačiulaitis R et al. Trends in the consumption of antidepressant drugs in Lithuania in 2002–2004. Medicina42, 1020–1029 (2006).
   PubMedGoogle Scholar
• Vlahović-Palcevski V, Gantumur M, Radoševic N et al. Coping with changes in the defined daily dose in a longitudinal drug consumption database. Pharm. World Sci.32, 125–129 (2010).
   PubMedGoogle Scholar
• Godman B, Sakshaug S, Berg C et al. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev. Pharmacoeconomics Outcomes Res.11, 121–129 (2011).
   PubMed Web of Science ®Google Scholar
• Seiter A. A Practical Approach to Pharmaceutical Policy. The World Bank. Washington DC, USA (2010).
   Google Scholar
• Martikainen J, Kivi I, Linnosmaa I. European prices of newly launched reimbursable pharmaceuticals – a pilot study. Health Policy74, 235–246 (2005).
   PubMed Web of Science ®Google Scholar
• Frank R, Salkever D. Generic entry and pricing of pharmaceuticals. J. Econ. Manag. Strategy6, 75–90 (1997).
   Web of Science ®Google Scholar
• Danzon PM, Chao LW. Cross-national price differences for pharmaceuticals: how large, and why? J. Health Econ.19, 159–195 (2000).
   PubMed Web of Science ®Google Scholar
• Wladysiuk M, Araszkiewicz A, Godman B et al. Patient co-payments do influence atypical antipsychotic choice in Poland: implications once generic atypcials are available. Appl. Health Econ. Health Policy9, 101–110 (2011).
   PubMedGoogle Scholar
• Godman B, Buscics A, Burkhardt T et al. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries. Expert Rev. Pharmacoeconomics Outcomes Res.10, 199–207 (2010).
   PubMed Web of Science ®Google Scholar